MA43723A - Essai employant la phagocytose à médiation cellulaire initié par anticorps pour mesurer des protéines agrégées - Google Patents

Essai employant la phagocytose à médiation cellulaire initié par anticorps pour mesurer des protéines agrégées

Info

Publication number
MA43723A
MA43723A MA043723A MA43723A MA43723A MA 43723 A MA43723 A MA 43723A MA 043723 A MA043723 A MA 043723A MA 43723 A MA43723 A MA 43723A MA 43723 A MA43723 A MA 43723A
Authority
MA
Morocco
Prior art keywords
cell mediated
mediated phagocytosis
aggregated protein
initiated cell
phagocytosis test
Prior art date
Application number
MA043723A
Other languages
English (en)
Inventor
Svetlana Bergelson
Carl Co
Allyson Masci
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MA43723A publication Critical patent/MA43723A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Peptides Or Proteins (AREA)
MA043723A 2016-03-14 2017-03-14 Essai employant la phagocytose à médiation cellulaire initié par anticorps pour mesurer des protéines agrégées MA43723A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662308082P 2016-03-14 2016-03-14

Publications (1)

Publication Number Publication Date
MA43723A true MA43723A (fr) 2021-05-19

Family

ID=58347346

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043723A MA43723A (fr) 2016-03-14 2017-03-14 Essai employant la phagocytose à médiation cellulaire initié par anticorps pour mesurer des protéines agrégées

Country Status (6)

Country Link
US (1) US11340225B2 (fr)
EP (2) EP3430397B1 (fr)
DK (1) DK3430397T3 (fr)
MA (1) MA43723A (fr)
PL (1) PL3430397T3 (fr)
WO (1) WO2017157961A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MA43723A (fr) 2016-03-14 2021-05-19 Biogen Int Neuroscience Gmbh Essai employant la phagocytose à médiation cellulaire initié par anticorps pour mesurer des protéines agrégées
SG11201906947SA (en) 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof
MA49947B1 (fr) 2017-08-22 2023-03-31 Biogen Ma Inc Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
EP3801618A4 (fr) * 2018-05-30 2022-07-27 National Health Research Institutes Anticorps anti-abeta et leurs utilisations
CN113711037A (zh) * 2019-04-18 2021-11-26 基因泰克公司 抗体效力测定
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
EP4288455A1 (fr) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Agents de liaison et leurs méthodes d'utilisation
US20240209080A1 (en) 2021-04-10 2024-06-27 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CN117203238A (zh) 2021-04-23 2023-12-08 普方生物制药美国公司 Cd70结合剂、其偶联物及其使用方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023076876A1 (fr) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation de réponses immunitaires à des vecteurs viraux
WO2023099788A1 (fr) 2021-12-03 2023-06-08 Neurimmune Ag Nouveau dosage de puissance pour des médicaments à base d'anticorps et moyens utiles associés
WO2024030956A2 (fr) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Agents de liaison se liant spécifiquement à cd39 et leurs méthodes d'utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030028904A1 (en) 2001-04-19 2003-02-06 Gumienny Tina L. Genes involved in engulfment of dying cells and cell migration
SG177954A1 (en) 2007-01-05 2012-02-28 Univ Zuerich Method of providing disease-specific binding molecules and targets
US7771957B2 (en) 2007-10-19 2010-08-10 The Regents Of The University Of California Method for diagnosing alzheimer's disease
EP2949666B1 (fr) 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Anticorps humains anti-alpha-synucléine
WO2012049570A1 (fr) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Anticorps anti-tau humain
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
SG11201401735WA (en) 2011-10-28 2014-05-29 Biogen Idec Internat Neuroscience Gmbh Tdp-43 specific binding molecules
LT2935326T (lt) 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
CN116396393A (zh) * 2015-10-08 2023-07-07 酵活英属哥伦比亚省公司 包含κ和λ轻链的抗原结合多肽构建体及其用途
MA43723A (fr) 2016-03-14 2021-05-19 Biogen Int Neuroscience Gmbh Essai employant la phagocytose à médiation cellulaire initié par anticorps pour mesurer des protéines agrégées

Also Published As

Publication number Publication date
DK3430397T3 (da) 2022-05-02
EP3430397A1 (fr) 2019-01-23
EP4063858A1 (fr) 2022-09-28
US11340225B2 (en) 2022-05-24
PL3430397T3 (pl) 2022-04-04
EP3430397B1 (fr) 2022-02-23
US20190079077A1 (en) 2019-03-14
WO2017157961A1 (fr) 2017-09-21

Similar Documents

Publication Publication Date Title
MA43723A (fr) Essai employant la phagocytose à médiation cellulaire initié par anticorps pour mesurer des protéines agrégées
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA47268A (fr) Anticorps anti-gpc3
CO2018005525A2 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA46057A (fr) Anticorps anti-ctla4
MA42626A (fr) Nouveaux anticorps anti-pd-1
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
JP2017532602A5 (ja) 画像ベースの測定および散乱測定ベースのオーバーレイ測定のための信号応答計測
MA46315A (fr) Polythérapies pour malignités hématologiques avec des anticorps anti-cd38 et des inhibiteurs de la survivine
MA47472A (fr) Anticorps
MA43417A (fr) Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations
MA50352A (fr) Anticorps multispécifiques
MA46540A (fr) Agonistes du récepteur de l'apéline (apj) hétérocyclique et leurs utilisations
MA46963A (fr) Méthodes pour déterminer le dosage de céllules car-t
MA45234A (fr) Anticorps anti-facteur xi de coagulation
MA42843A (fr) Anticorps anti-cd115
MA44236A (fr) Anticorps anti-tgfbêta 2
MA51134A (fr) Anticorps anti-alpha-synucléine
MA45573A (fr) Anticorps anti-cd154 et procédés d'utilisation correspondant
TWD183789S (zh) 捲尺之部分（一）